User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Current and Future Analysis.....II-1
Monoclonal Antibody Market Garners Riches.....II-1
1$100
   Rituxan/MabThera to Remain the Market Leader.....II-2
Rituxan’s Success Spurs Development of New Anti-CD20 Antibodies.....II-2
Clinical Trial Failures Trouble Drug Makers, Retracts Market Growth.....II-2
1$100
   Safety Issues Marr Penetration of Radiolabelled CD20 Antibodies.....II-3
Oncologists Resort to Zevalin and Bexxar As a Last Resort.....II-3
Novel Action Mechanisms Bode Potential for New CD20 mAbs.....II-3
1$100
   Future of mAbs – Smaller and Inexpensive to Produce.....II-4
Structurally Modified Full-Size mAbs – Next Type of mAbs to Hit the Market.....II-4
1$100
   MAb Fragments.....II-5
Major Companies in the Chase for New-Generation Technologies.....II-5
Next Generation CD20 mABs.....II-5
1$100
   Comparison of Marketed and Pipeline CD20 Antibodies Based on Action Mechanism.....II-6
Second Generation CD20 Antibodies.....II-6
Ofatumumab.....II-6
Veltuzumab.....II-6
Ocrelizumab.....II-6
1$100
   Third Generation CD20 Antibodies.....II-7
AME133v.....II-7
TRU-015.....II-7
GA101/Obinutuzumab.....II-7
Incidence and Prevalence of Major Targeted Indications of CD20 mAbs.....II-7
Rheumatoid Arthritis – A Chronic, Debilitating Disease.....II-7
1$100
   Incidence and Prevalence Higher in Urban and Developed Regions.....II-8
Lymphoma Incidence and Mortality Rates On the Rise.....II-8
Incidence of Hodgkin's Lymphoma - High in West Asia.....II-8
1$100
   Table 1: Age-Standardized Incidence Rates for Hodgkin’s Lymphoma in Select Countries Worldwide (2002) (includes corresponding Graph/Chart).....II-9

Table 2: Age-Standardized Mortality Rates for Hodgkin’s Lymphoma in Select Countries Worldwide (2002) (includes corresponding Graph/Chart).....II-9
1$350
   PML Risks Clipping Label Expansions of Rituxan.....II-10
Rituxan and Ocrelizumab Show Promise in RRMS Treatment.....II-10
1$100
   Ocrelizumab’s Ouster in RA Puts Development Partners in a Quandary.....II-11
Zevalin and Bexxar Sales Remain in Obscurity.....II-11
1$100
   The Road Ahead for Zevalin.....II-121$100
   Approved Anti-CD20 Antibodies in a Nutshell.....II-13
Select Anti-CD20 Antibodies’ Pipeline in a Nutshell.....II-13
2$125
   Drug Details.....II-15
Rituxan/MabThera (Biogen, Roche and Genentech).....II-15
1$100
   Approved and Potential Indications for Rituxan.....II-16
Zevalin (Spectrum™ Pharmaceuticals).....II-16
Bexxar (GlaxoSmithKline).....II-16
1$100
   Ofatumumab (Genmab and GlaxoSmithKline).....II-17
Clinical Development of HuMax-CD20 by Indication and Stage of Development.....II-17
1$100
   Ocrelizumab (Biogen/Genentech).....II-18
Summary of Ocrelizumab Development Status.....II-18
GA-101 (Roche/GlycArt).....II-18
1$100
   TRU-015 (Trubion).....II-19
AME-133v (Eli Lilly).....II-19
1$100
   Veltuzumab (Immunomedics/Nycomed).....II-201$100
   Clinical Trials of Veltuzumab.....II-21
BVX-20 (Biocon).....II-21
LFB-R603 (LFB Biotechnlogies).....II-21
DXL625 (InNexus).....II-21
1$100
   CD20 Antibody.....II-22
Immune System: Natural Defenders.....II-22
Human Antibodies.....II-22
Types of Monoclonal Antibodies.....II-22
Table 3: Worldwide mAb Market by Product Type (2008): Percentage Share Breakdown for Chimeric, Humanized, Human, and Murine (includes corresponding Graph/Chart).....II-22
1$350
   Chimeric Antibodies: Show Lesser Antigenicity.....II-23
Murine Monoclonal Antibodies.....II-23
Humanized Antibodies/ CDR Grafted Antibodies (Human Antibodies).....II-23
1$100
   Fully Human Antibodies.....II-24
Bispecific Antibodies.....II-24
1$100
   Evolution of Monoclonal Antibodies – A Historical Journey.....II-251$100
   Market Perspective of mAbs.....II-26
Regional Perspective.....II-26
Significant Growth Awaits mAbs.....II-26
1$100
   Shift Towards Humanized and Fully Human Antibodies.....II-27
Ageing Baby Boomers Spur MAbs Growth.....II-27
1$100
   Non-Existent Generic Competition Favors MAb Market.....II-28
Rising Number of MAbs Under Clinical Trials.....II-28
High Costs Impede MAbs Penetration.....II-28
1$100
   Opportunities in Technology Development.....II-29
Advancements & Challenges in Antibody Production Processes.....II-29
Increasing Demand for Protein A in MAb Manufacturing.....II-29
1$100
   Rituxan Receives FDA Approval for the Treatment of Chronic Lymphocytic
  Leukemia.....II-30
GSK Receives Positive Opinion for Arzerra™ from EMEA.....II-30
LFB Obtains Orphan Drug Status for LFB-R603 in Europe.....II-30
1$100
   FDA Grants Accelerated Approval for GSK and Genmab’s Ofatumumab for Chronic Lymphocytic
  Leukemia.....II-31
InNexus’s DXL625 Receives Positive Opinion from FDA.....II-31
1$100
   Spectrum Pharma Obtains FDA Approval for Zevalin’s Expanded Label in NHL
  Treatment.....II-32
Bayer Schering Obtains EU Approval for Zevalin in First-Line Treatment.....II-32
1$100
   Pfizer Discontinues Development of TRU-015; Continues to Develop SBI-087.....II-33
Roche and Biogen Discontinue Ocrelizumab Development in Rheumatoid Arthritis.....II-33
1$100
   Roche and Biogen File Patent Suit Against GSK.....II-34
Ocrelizumab Meets Primary End-Point In Phase III Trial for RA.....II-34
Rituxan Plus FC Chemotherapy Shows Improved Survival in Treatment-Naïve CLL
  Patients.....II-34
1$100
   FDA Declines Early Use of Rituxan in RA.....II-35
LG Life Sciences Announces New Anti-CD20 Antibody Program.....II-35
Provenance Acquires Global Rights to New Anti-CD20 Antibody from Merck.....II-35
Roche Takes Over Genentech.....II-35
Pfizer Acquires Wyeth.....II-35
1$100
   Spectrum Pharma Acquires Lymphoma Drug Zevalin.....II-36
Biogen Partners with Genentech and Roche for Development of GA-101.....II-36
Roche, GlycArt and Genentech Team Up for Development of GA-101.....II-36
1$100
   InNexus Biotechnology Discovers New Anti-CD20 Antibody, DXLr120.....II-37
MRC Completes Humanization of Biolex’s Anti-CD20 Antibody, BLX-301.....II-37
Immunomedics Inks Licensing and Collaboration Deal with Nycomed.....II-37
Rituxan Fails To Meet Primary End-Point in Phase II/III Trial for SLE.....II-37
1$100
   Rituxan Fails To Meet Primary End-Point in Phase II/III Trial for PPMS.....II-38
Rituxan Meets Primary End-point in Phase III Trial for DMARD Inadequate Responders in
  RA.....II-38
Cell Therapeutics Acquires Zevalin from Biogen Idec.....II-38
1$100
   InNexus Develops Dxl625 Anti-Cd20 Monoclonal Antibody.....II-39
GTC and LFB Commence Development of Novel Anti-CD20 Antibody.....II-39
Favrille Purchases Anti-CD20 mAbs from Diversa.....II-39
Genmab and GSK Ink Global Collaboration Agreement for HuMax-CD20.....II-39
2$125
   Bayer Schering Pharma AG (Germany).....II-41
Biocon (India).....II-41
1$100
   Biogen Idec, Inc. (US).....II-421$100
   Eli Lilly and Company (US).....II-43
F. Hoffmann-La Roche Ltd. (Switzerland).....II-43
1$100
   Genentech, Inc. (US).....II-44
Genmab A/S (Denmark).....II-44
1$100
   GlaxoSmithKline Plc. (UK).....II-45
GTC Biotherapeutics, Inc. (US).....II-45
1$100
   Immunomedics, Inc. (US).....II-46
InNexus Biotechnology, Inc. (Canada).....II-46
1$100
   LFB Group (France).....II-47
Nycomed (Switzerland).....II-47
1$100
   Pfizer, Inc. (US).....II-48
Spectrum Pharmaceuticals, Inc. (US).....II-48
1$100
   Trubion Pharmaceuticals, Inc......II-491$100
   UCB Pharmaceutical (Belgium).....II-501$100
   Table 4: World Recent Past, Current & Future Analysis for Anti-CD20 Antibodies Market by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-511$350
   Table 5: World 10-year Perspective for Anti-CD20 Antibodies Market by Geographic Region - Percentage Breakdown of Value Sales for US and Rest of World Markets for Years 2006, 2010 & 2015 (includes corresponding Graph/Chart).....II-521$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com